Clinical Trial Update: A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 4]

View source ↗

Summary

The Phase 4 trial evaluating the radiological onset of action after starting subcutaneous natalizumab in relapsing-remitting multiple sclerosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: TERMINATED